State-of-the-art medical prevention of postoperative recurrence of Crohn's disease

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 7, 2013, Pages 413-422

  Sorrentino, Dario ^a,b  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; ORNIDAZOLE; PLACEBO; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

CAPSULE ENDOSCOPY; CHEMOPROPHYLAXIS; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FECES ANALYSIS; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE RECURRENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DISEASE MANAGEMENT; HUMANS; POSTOPERATIVE PERIOD; RECURRENCE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879923671     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.69     Document Type: Review

References (123)

1. Sandborn, W. J. et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122, 512-530 (2002).
2. Sorrentino, D. & Paviotti, A. Postsurgical recurrence of Crohn's disease: the beginning of the end? Gastroenterology 137, 1181-1182 (2009).
3. Regueiro, M. et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm. Bowel Dis. 17, 118-126 (2011).
4. Hanauer, S. B. et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127, 723-729 (2004).
5. Sorrentino, D., Terrosu, G., Avellini, A. & Maiero, S. Infliximab and low dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn's disease. Arch. Intern. Med. 167, 1804-1810 (2007).
6. Walters, T. D. et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm. Bowel Dis. 17, 1547-1556 (2011).
7. Rutgeerts, P. et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99, 956-963 (1990).
8. Sachar, D. B. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut 55, 1069-1070 (2006).
9. Terdiman, J. P. Prevention of postoperative recurrence in Crohn's disease. Clin. Gastroenterol. Hepatol. 6, 616-620 (2008).
10. Lamb, C. A. et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br. J. Surg. 96, 663-674 (2009).
11. Sorrentino, D. et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab-a pilot study. Dig. Dis. Sci. 57, 1341-1348 (2012).
12. Bourreille, A. et al. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut 55, 978-983 (2006).
13. Koilakou, S. et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm. Bowel Dis. 16, 198-203 (2010).
14. Soyer, P. et al. Suspected anastomotic recurrence of Crohn disease after ileocolic resection: evaluation with CT enteroclysis. Radiology 254, 755-764 (2010).
15. Castiglione, F. et al. Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflamm. Bowel Dis. 14, 1240-1245 (2008).
16. Sachar, D. B. et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm. Bowel Dis. 15, 1071-1075 (2009).
17. Watanabe, T. et al. Interval of less than 5 years between the first and second operation is a risk factor for a third operation for Crohn's disease. Inflamm. Bowel Dis. 18, 17-24 (2012).
18. Buisson, A., Chevaux, J. B., Allen, P. B., Bommelaer, G. & Peyrin-Biroulet, L. The natural history of post-operative Crohn's disease recur rence. Aliment. Pharmacol. Ther. 35, 625-633 (2012).
19. Ferrante, M. et al. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology 130, 1595-1606 (2006).
20. Ng, S. C. et al. Predictive value and clinical significance of myenteric plexitis in Crohn's disease. Inflamm. Bowel Dis. 15, 1499-1507 (2009).
21. Sokol, H. et al. Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. Gut 58, 1218-1225 (2009).
22. Simillis, C., Jacovides, M., Reese, G. E., Yamamoto, T. & Tekkis, P. P. Meta-analysis of the role of granulomas in the recurrence of Crohn disease. Dis. Colon Rectum 53, 177-185 (2010).
23. Bernell, O., Lapidus, A. & Hellers, G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br. J. Surg. 87, 1697-1701 (2000).
24. Yamamoto, T., Allan, R. N. & Keighley, M. R. Longterm outcome of surgical management for diffuse jejunoileal Crohn's disease. Surgery 129, 96-102 (2001).
25. Poggioli, G. et al. Factors affecting recurrence in Crohn's disease. Results of a prospective audit. Int. J. Colorectal Dis. 11, 294-298 (1996).
26. De Cruz, P., Kamm, M. A., Prideaux, L., Allen, P. B. & Desmond, P. V. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm. Bowel Dis. 18, 758-777 (2012).
27. Reese, G. E. et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int. J. Colorectal Dis. 23, 1213-1221 (2008).
28. Yamamoto, T. & Keighley, M. R. Smoking and disease recurrence after operation for Crohn's disease. Br. J. Surg. 87, 398-404 (2000).
29. Cottone, M. et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 106, 643-648 (1994).
30. McLeod, R. S. et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 113, 1823-1827 (1997).
31. Scarpa, M. et al. Surgical predictors of recurrence of Crohn's disease after ileocolonic resection. Int. J. Colorectal Dis. 22, 1061-1069 (2007).
32. Maconi, G. et al. CARD15 gene variants and risk of reoperation in Crohn's disease patients. Am. J. Gastroenterol. 104, 2483-2491 (2009).
33. Caprilli, R. et al. Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Dis. Colon Rectum 39, 335-341 (1996).
34. Post, S. et al. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. Ann. Surg. 223, 253-260 (1996).
35. Kinchen, J., Rajaratnam, K., Kingston, G., Mee, A. S. & De Silva, A. N. The presence of microscopic disease at the resection margins predicts post-surgical relapse in Crohn's Disease. Gastroenterology 142, S1068 (2012).
36. Fazio, V. W. et al. Effects of resection margin on the recurrence of Crohn's disease in the small bowel: a randomized controlled trial. Ann. Surg. 224, 563-571 (1996).
37. Renna, S. et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 135, 1500-1509 (2008).
38. McLeod, R. S. et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 109, 404-413 (1995).
39. Brignola, C. et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 108, 345-349 (1995).
40. Sutherland, L. R. et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 112, 1069-1077 (1997).
41. Lochs, H. et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 118, 264-273 (2000).
42. Caprilli, R. et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: A pragmatic, double-blind, randomized controlled trial. Aliment. Pharmacol. Ther. 17, 517-523 (2003).
43. Camma, C., Giunta, M., Rosselli, M. & Cottone, M. Mesalamine in the maintenance treatment of Crohn's disease: A metaanalysis adjusted for confounding variables. Gastroenterology 113, 1465-1473 (1997).
44. Doherty, G., Bennett, G., Patil, S., Cheifetz, A. & Moss, A. C. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD006873 http://dx.doi.org/10.1002/14651858.CD006873.pub2 (2009).
45. Ford, A. C. et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106, 617-629 (2011).
46. Ewe, K., Herfarth, C., Malchow, H. & Jesdinsky, H. J. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A multicenter trial. Digestion 42, 224-232 (1989).
47. Ewe, K., Bottger, T., Buhr, H. J., Ecker, K.-W. & Otto, H. F. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur. J. Gastroenterol. Hepatol. 11, 277-282 (1999).
48. Hellers, G. et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 116, 294-300 (1999).
49. Rutgeerts, P. et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108, 1617-1621 (1995).
50. Rutgeerts, P. et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128, 856-861 (2005).
51. Ardizzone, S. et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127, 730-740 (2004).
52. Sandborn, W. J. & Feagan, B. G. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 127, 990-993 (2004).
53. Papay, P. et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am. J. Gastroenterol. 105, 1158-1164 (2010).
54. D'Haens, G. et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's Disease: a controlled randomized trial. Gastroenterology 135, 1123-1129 (2008).
55. Herfarth, H. et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 55, 1525-1526 (2006).
56. Peyrin-Biroulet, L. et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am. J. Gastroenterol. 104, 2089-2096 (2009).
57. Colombel, J. F. et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49, 42-46 (2001).
58. Esaki, M. et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand. J. Gastroenterol. 40, 1431-1437 (2005).
59. Yamamoto, T., Nakahigashi, M., Umegae, S., Kitagawa, T. & Matsumoto, K. Impact of longterm enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: a prospective, non-randomized, parallel, controlled study. Aliment. Pharmacol. Ther. 25, 67-72 (2007).
60. Yamamoto, T., Shiraki, M., Nakahigashi, M., Umegae, S. & Matsumoto, K. Enteral nutrition to suppress postoperative Crohn's disease recurrence: a five-year prospective cohort study. Int. J. Colorectal Dis. 28, 335-340 (2013).
61. Prantera, C., Scribano, M. L., Falasco, G., Andreoli, A. & Luzi, C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 51, 405-409 (2002).
62. Marteau, P. et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 55, 842-847 (2006).
63. Van Gossum, A. et al. Multicenter randomized controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm. Bowel Dis. 13, 135-142 (2007).
64. Chermesh, I. et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig. Dis. Sci. 52, 385-389 (2007).
65. Rutgeerts, P. et al. Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338, 771-774 (1991).
66. D'Haens, G. et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114, 262-267 (1998).
67. Fichera, A., McCormack, R., Rubin, M. A., Hurst, R. D. & Michelassi, F. Long-term outcome of surgically treated Crohn's colitis: a prospective study. Dis. Colon Rectum 48, 963-969 (2005).
68. Amiot, A. et al. Crohn's disease recurrence after total proctocolectomy with definitive ileostomy. Dig. Liver Dis. 43, 698-702 (2011).
69. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
70. D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660-667 (2008).
71. Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
72. Hyams, J. et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132, 863-873 (2007).
73. Peyrin-Biroulet, L., Bigard, M. A., Malesci, A. & Danese, S. Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late. Gastroenterology 135, 1420-1422 (2008).
74. Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52-65 (2007).
75. Schreiber, S. et al. Increased response and remission rates in short duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECISE 2 randomized maintenance trial data. Am. J. Gastroenterol. 105, 1574-1582 (2010).
76. Sorrentino, D. et al. Prevention of postoperative recurrence of Crohn's disease by Infliximab. Eur. J. Gastroenterol. Hepatol. 18, 457-459 (2006).
77. Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003).
78. Sorrentino, D. et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin. Gastroenterol. Hepatol. 8, 591-599 (2010).
79. Hanauer, S. B. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 56, 1181-1183 (2007).
80. Regueiro, M. et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136, 441-450 (2009).
81. Baars, J. E., Nuij, V. J., Oldenburg, B., Kuipers, E. J. & van der Woude, C. J. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm. Bowel Dis. 18, 1634-1640 (2012).
82. Sorrentino, D. Mucosal healing and clinical remission in inflammatory bowel diseases: Are we missing something here? Inflamm. Bowel Dis. 19, E55-E56 (2013).
83. Yoshida, K. et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm. Bowel Dis. 18, 1617-1623 (2012).
84. Sakuraba, A. et al. The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot, open-labeled prospective study. Int. J. Colorectal Dis. 27, 947-952 (2012).
85. Tarekegn, S. et al. Biologics are superior to immunomodulators in prevention of postoperative recurrence of Crohn's disease. Gastroenterology 140, S-592 (2011).
86. Papamichael, K., Archavlis, E., Lariou, C. & Mantzaris, G. J. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study. J. Crohns Colitis 6, 924-931 (2012).
87. Savarino, E., Dulbecco, P., Bodini, G., Assandri, L. & Savarino, V. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. Eur. J. Gastroenterol. Hepatol. 24, 468-470 (2012).
88. Aguas, M. et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients World J. Gastroenterol. 18, 4391-4398 (2012).
89. Fernandez-Blanco, I., Monturiol, J. & Martinez, B. Adalimumab in the prevention of postoperative recurrence of Crohn's disease. Gastroenterology 138, S692 (2010).
90. De Cruz, P. et al. Adalimumab prevents postoperative Crohn's disease recurrence, and is superior to thiopurines: early results from the POCER Study. Gastroenterology 142, S212 (2012).
91. Hellers, G. Crohn's disease in Stockholm county 1955-1974 A study of epidemiology, results of surgical treatment and long-term prognosis. Acta Chir. Scand. Suppl. 490, 1-84 (1979).
92. Biancone, L. et al. Local injection of Infliximab in the postoperative recurrence of Crohn's disease. Gastrointest. Endosc. 63, 486-492 (2006).
93. Yamamoto, T., Umegae, S. & Matsumoto, K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm. Bowel Dis. 15, 1460-1466 (2009).
94. Boueyre, E. et al. Efficacy of anti-TNF on severe postoperative endoscopic recurrence in Crohn's disease. Gastroenterology 142, S-660 (2012).
95. Regueiro, M. et al. 4.5 Yr follow-up of patients enrolled in the randomized controlled trial (RCT) of infliximab (Inf) for prevention of postoperative Crohn's disease (CD). Gastroenterology 138, S694 (2010).
96. Gisbert, J. P. & Panés, J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 104, 760-767 (2009).
97. Danese, S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig. Liver Dis. 40, S225-S228 (2008).
98. Barnes, M. J. & Powrie, F. Regulatory T cells reinforce intestinal homeostasis. Immunity 31, 401-411 (2009).
99. Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898 (2009).
100. Bernstein, C. N. Anti-tumor necrosis factor therapy in Crohn's disease: more information and more questions about the long term. Clin. Gastroenterol. Hepatol. 8, 556-558 (2010).
101. Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142, 63-70 (2012).
102. Waugh, A. W. et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment. Pharmacol. Ther. 32, 1129-1134 (2010).
103. Schnitzler, F. et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58, 492-500 (2009).
104. Baert, F. et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138, 463-468 (2010).
105. Steenholdt, C. et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand. J. Gastroenterol. 47, 518-527 (2012).
106. Sorrentino, D. et al. Low dose infliximab for prevention of postoperative recurrence of Crohn's disease: long term follow-up and impact of infliximab trough levels and antibodies to infliximab. Gastroenterology (in press).
107. Van de Casteele, N. et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial. Gastroenterology 142, S1159 (2012).
108. Steenholdt, C. et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand. J. Gastroenterol. 46, 310-318 (2011).
109. Cassinotti, A. & Travis, S. Incidence and clinical significance of immunogenicity to infliximab in sCrohn's disease: a critical systematic review. Inflamm. Bowel Dis. 15, 1264-1275 (2009).
110. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295, 2275-2278 (2006).
111. Buisson, A., Chevaux, J. B., Bommelaer, G. & Peyrin-Biroulet, L. Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Dig. Liver Dis. 44, 453-460 (2012).
112. Schwartz, M. & Regueiro, M. Prevention and treatment of postoperative Crohn's disease recurrence: an update for a new decade. Curr. Gastroenterol. Rep. 13, 95-100 (2011).
113. Spinelli, A., Sacchi, M., Fiorino, G., Danese, S. & Montorsi, M. Risk of postoperative recurrence and postoperative management of Crohn's disease. World J. Gastroenterol. 17, 3213-3219 (2011).
114. Van Assche, G. et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J. Crohns Colitis 4, 63-101 (2010).
115. Peyrin-Biroulet, L., Oussalah, A., Roblin, X. & Sparrow, M. P. The use of azathioprine in Crohn's disease during pregnancy and in the postoperative setting: a worldwide survey of experts. Aliment. Pharmacol. Ther. 33, 707-713 (2011).
116. Yamamoto, T. Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. World J. Gastroenterol. 16, 5405-5410 (2010).
117. Borowiec, A. M. & Fedorak, R. N. Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field. Can. J. Gastroenterol. 25, 140-146 (2011).
118. De Cruz, P. et al. Clinical risk stratification predicts development of endoscopic recurrence after Crohn's disease surgery: early results from the POCER Study. Gastroenterology 142, S568 (2012).
119. Kandiel, A. et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54, 1121-1125 (2005).
120. Reinisch, W. et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 59, 752-759 (2010).
121. Yamamoto, T., Fazio, V. W. & Tekkis, P. P. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. Dis. Colon Rectum 50, 1968-1986 (2007).
122. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01190839 (2013).
123. Danese, S., Fiorino, G. & Reinisch, W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Aliment. Pharmacol. Ther. 34, 1-10 (2011).